<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>00840140707083</udiDi>
    <basicUdiDi>B-00840140707083</basicUdiDi>
    <tradeName>Glypican 3</tradeName>
    <deviceName>Glypican 3</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2103MT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:54.420Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140707076</udiDi>
    <basicUdiDi>B-00840140707076</basicUdiDi>
    <tradeName>Glypican 3</tradeName>
    <deviceName>Glypican 3</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2103MS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:53.593Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140707069</udiDi>
    <basicUdiDi>B-00840140707069</basicUdiDi>
    <tradeName>Glypican 3</tradeName>
    <deviceName>Glypican 3</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2103ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:49.588Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706970</udiDi>
    <basicUdiDi>B-00840140706970</basicUdiDi>
    <tradeName>Glucagon</tradeName>
    <deviceName>Glucagon</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2299RP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:48.792Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706963</udiDi>
    <basicUdiDi>B-00840140706963</basicUdiDi>
    <tradeName>Glucagon</tradeName>
    <deviceName>Glucagon</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2299RT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:47.987Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706956</udiDi>
    <basicUdiDi>B-00840140706956</basicUdiDi>
    <tradeName>Glucagon</tradeName>
    <deviceName>Glucagon</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2299RS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:47.188Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706949</udiDi>
    <basicUdiDi>B-00840140706949</basicUdiDi>
    <tradeName>Glucagon</tradeName>
    <deviceName>Glucagon</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2299RL</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:43.178Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706932</udiDi>
    <basicUdiDi>B-00840140706932</basicUdiDi>
    <tradeName>GFAP</tradeName>
    <deviceName>GFAP</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2255MP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:42.380Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706901</udiDi>
    <basicUdiDi>B-00840140706901</basicUdiDi>
    <tradeName>GFAP</tradeName>
    <deviceName>GFAP</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2255ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:41.722Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706925</udiDi>
    <basicUdiDi>B-00840140706925</basicUdiDi>
    <tradeName>GFAP</tradeName>
    <deviceName>GFAP</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2255MT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:41.587Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706918</udiDi>
    <basicUdiDi>B-00840140706918</basicUdiDi>
    <tradeName>GFAP</tradeName>
    <deviceName>GFAP</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2255MS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:38.507Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706895</udiDi>
    <basicUdiDi>B-00840140706895</basicUdiDi>
    <tradeName>GCDFP-15</tradeName>
    <deviceName>GCDFP-15</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2345MP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:22.344Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706888</udiDi>
    <basicUdiDi>B-00840140706888</basicUdiDi>
    <tradeName>GCDFP-15</tradeName>
    <deviceName>GCDFP-15</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2345MT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:21.531Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706871</udiDi>
    <basicUdiDi>B-00840140706871</basicUdiDi>
    <tradeName>GCDFP-15</tradeName>
    <deviceName>GCDFP-15</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2345MS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:20.739Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706864</udiDi>
    <basicUdiDi>B-00840140706864</basicUdiDi>
    <tradeName>GCDFP-15</tradeName>
    <deviceName>GCDFP-15</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2345ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:19.930Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706819</udiDi>
    <basicUdiDi>B-00840140706819</basicUdiDi>
    <tradeName>GATA-3</tradeName>
    <deviceName>GATA-3</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2227MP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:15.923Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706802</udiDi>
    <basicUdiDi>B-00840140706802</basicUdiDi>
    <tradeName>GATA-3</tradeName>
    <deviceName>GATA-3</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2227MT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:15.128Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706796</udiDi>
    <basicUdiDi>B-00840140706796</basicUdiDi>
    <tradeName>GATA-3</tradeName>
    <deviceName>GATA-3</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2227MS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:14.318Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706789</udiDi>
    <basicUdiDi>B-00840140706789</basicUdiDi>
    <tradeName>GATA-3</tradeName>
    <deviceName>GATA-3</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2227ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:13.520Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140706536</udiDi>
    <basicUdiDi>B-00840140706536</basicUdiDi>
    <tradeName>Fascin</tradeName>
    <deviceName>Fascin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2446MP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-07-04T20:32:09.529Z</lastUpdated>
  </row>
</eudamedExport>